Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects

First Author

Publication Year

Number of Leukemia Cases (male/female)

Number of Controls (male/female)

Number of AML cases

Type of controls

Median (or mean) age, (range) year (Cases/Controls)

Racial decent

Country

Balta

2003

33 (19/14)

185 (120/65)

33 AML

Healthy controls (PB)

8.7(1–17)/7.4(0.58-17)

Mixed

Turkey

D'Alo

2004

193 (107/86)

273(147/126)

193 AML

Healthy controls (PB)

62(19–87)/60(19–90)

Caucasian

Italy

Clavel

2005

219 (129/90)

105 (57/48)

28 AML

Non-cancer controls (age,- gender-, hospital-, ethnicity-matched; HB)

NA(0–15)/NA(0–15)

Mixed

France

Aydin-Sayitoglu

2006

249 (143/106)

140 (73/67)

50 adult AML; 44 pediatric AML

Healthy controls (PB)

Adult:33(19–75); pediatric: 7.8(2–18)/28.7(16–59)

Caucasian

Turkey

Bolufer

2007

443 (223/190)

454 (223/231)

302 AML

Healthy controls (PB)

39.48(0.8-84)/38.38(1–85)

Caucasian

Spain

Jiang

2008

98 (NA)

120 (NA)

98 AML

Healthy controls (age-, sex-matched; PB)

NA(16–68)/NA(16–68)

Asian

China

Majumdar

2008

110 (70/40)

126 (54/72)

110 AML

Healthy controls (PB)

35(4–81)/30(8–73)

Asian

India

Yamaguti

2009

133 (70/63)

133 (70/63)

133 AML

Healthy controls (PB)

47(11–89)/53(25–60)

Mixed

Brazil

Bonaventure

2012

493 (266/227)

549 (292/257)

51 AML

Healthy controls (age-, gender-matched; PB)

NA(0–15)/NA(0–15)

Caucasian

France

Kim

2012

415 (223/192)

1700 (821/879)

415 AML

Healthy controls (PB)

50.5(15–86)/52.2(20–74)

Asian

Korea

  1. NA: not available; AML, acute myeloid leukemia; PB: population-based; HB: hospital-based.